Coronavirus Vaccine: Corona vaccine registration in Russia on August 12, vaccination starts from October
3 min read
Russia’s Health Minister Mikhail Murashko has announced that Russia’s vaccine has been 100% successful in clinical trials. He also announced to start vaccination of people on a large scale in the country from October. The government will bear all the expenses incurred in applying this vaccine. At the same time, Deputy Health Minister Oleg Gridnev said that Russia will register the world’s first corona virus vaccine on August 12. Gridnev said that the third phase of the vaccine is currently underway. He said that the results of the first two phases were 100 percent correct. This vaccine has been prepared by the Russian Ministry of Defense and the Gamalaya National Center for Research.
Russia said that all those who were given this vaccine in clinical trials were found to have immunity to SARS-COV-2. The trial started 42 days ago. At that time, volunteers were administered a corona vaccine at the Burdenko military hospital in Moscow. These people came to the hospital again on Monday and were intensively examined. During this time it was found that all people have developed immunity against the corona virus.
After this result, the government has praised the Russian vaccine. Russia’s Ministry of Defense said that the results of the review showed that a strong immune response has developed in the people due to the vaccine. Said that no negative side effects occurred in any volunteer.
Claim: 100% successful in corona vaccine trial, government will bear the cost of vaccine
- Russia will make 200 million doses of vaccine
- Russia will make three million doses of its virus vaccine in the country
- 17 crore doses of this vaccine will be made abroad.
- This month, production will start with approval in Russia and other countries in September.
Aurobindo Pharma, working on Kovid-19 vaccine, got approval: Aurobindo Pharma Ltd is working on making several vaccines including Kovid-19 vaccine and has been approved for funding by the Department of Biotechnology. The company said that many virus vaccines have been developed using R&D assets. The company has successfully completed the first and second phases. Phase III study is expected to begin by December 2020.
One lakh cases increasing in two days, doubling healthy compared to active cases: The number of corona infected in the world has reached 1.90 crore. At the same time, the death toll has reached beyond seven lakhs. Here, for the last eight days more than 50 thousand cases are coming to India. The good thing is that active cases are decreasing and the number of people recovering has more than doubled from the number of active cases. On Thursday, 62,538 new cases were reported in India, due to which the number of corona cases in the country has reached 20,27,075. So far, a total of 13,78,106 patients have beaten the corona. While 41,585 patients have died.
50 percent of cases in four states of the country : About 50% of the cases in the country are from only four states. The total number of infected in Maharashtra alone is about one fourth of the total number of the country. It is followed by Tamil Nadu, Andhra Pradesh and Karnataka.
- There are 20,33,847 total corona cases in the country
- There are 6,10,494 active cases
- 13,81,214 have been recovered
50 percent of cases in four states of the country : About 50% of the cases in the country are from only four states. The total number of infected in Maharashtra alone is about one fourth of the total number of the country. It is followed by Tamil Nadu, Andhra Pradesh and Karnataka.
Serum Institute India to produce 100 million vaccines, will be priced at Rs 235: New Delhi. The Serum Institute of India said on Friday that it has tied up with Gavi and the Bill & Melinda Gates Foundation to produce 100 million doses of the Kovid-19 vaccine for India and other low and middle-income countries. The Serum Institute said in a statement that the tie-up would provide upfront capital to the Serum Institute to help increase manufacturing capacity.
So that once a vaccine or vaccine is approved by the regulatory approvals and the World Health Organization, Gavi Kovacs AMC can produce enough doses for distribution in India and other low-middle income countries by the first half of 2021. . The company said that it has set an affordable rate of three dollars per dose i.e. about 225 rupees. This financing will also provide support in the manufacture of potential vaccines for AstraZeneca and Novavax.
